Thank you to our speakers, sponsors, and delegates who joined us in April for the summit!
If you are interested in the 2024 event, please get in touch at info@hansonwade.com
The Only Biophysics Specific Drug Discovery Meeting for the Biopharma Industry
Advance Biophysics Technologies & Applications to Measure Molecular & Target Interactions
The Biophysics for Drug Discovery Summit was the definitive, industry-dedicated forum that brought the latest advancements, discoveries, applications, and transferrable lessons of utilizing biophysical techniques across modalities and targets, to inform efficient drug discovery.
With new technologies emerging and existing techniques being refined, this summer uncovered the most advantageous approach in biopharma’s arsenal to uncover molecular and target interactions to maximize drug discovery and create a new era of transformative therapies.
This summed shared exclusive insights from Pfizer, UCB, Roche, Eli Lily, Boehringer Ingelheim, GSK, Merck, Sanofi alongside numerous leading biotech across three-days of unmissable content.
20+ World-Class Speaker Faculty Included:
Haihong Zhou
Senior Principal Scientist, Mass Spectrometry & Biophysics, Quantitative Biosciences
Merck
Companies Attended:
Top Testimonials
“All things in the universe are governed by a certain set of laws. Understanding those laws and applying them to drug discovery excites me. I look forward to learning more about the inclusion of biophysics in the drug development process.”
Kyle Martin, Senior Scientist, Boehringer Ingelheim
“The drug target space that is accessible with biophysical approaches is constantly growing due to innovation in protein science and refinement of biophysical techniques. The Biophysics in Drug Discovery Summit brings together experts from across the industry to exchange on recent advancements in the field.”
Arne Rufer, Expert Scientist, Lead Discovery, Roche
“This conference has a fantastic line-up of speakers and will help clarify the suitability of different biophysical techniques tailored to different target types and different questions in the process of small molecule drug invention.”
Laura Silvian, Senior Director, Biogen
Events in the Series
